perpetate	
It is made available under a CC-BY	4.0 International license .

1	Insulin resistance assessed by short insulin tolerance
2	test and its association with obesity and insulin
3	resistance-related parameters in humans :A
4	randomized trial
5	
6	Short title: Association of insulin resistance with its parameters and obesity
7	Aleiles Henry aleileited (Tales Weterscholtz Niesles Compleil (Taskitales Nielesch) Assolution
8	Akiko Hayashishita', Taku Watanabe''', Naoko Suzuki', Toshitaka Nakaya', Ayako
9 10	Sugimoto', Isao Yokota-, Hiroshi Onira', Masanaru Nishimura', Ichizo I sujino'
10	<sup>1</sup> Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University
12	Sannoro Hokkaido Janan
13	<sup>2</sup> Department of Biostatistics, Graduate school of Medicine, Hokkaido University,
14	Sapporo, Hokkaido, Japan
15	
16	*Corresponding author
17	Email: HYPERLINK "mailto:taku.watanabe@gmail.com"taku.watanabe@gmail.com
18	(TW)
19	ORCID NUMBER
20	0000-0002-3195-2413
21	
22	
23	

#### Abstract 24

25 The aim of this study was to examine the association of insulin resistance (evaluated by the short 26 insulin tolerance test [SITT]) with parameters related to obesity and insulin resistance. We prospectively 27 recruited controls and patients with type 2 diabetes mellitus (T2DM), subjected them to the SITT, and 28 calculated the K indices of the intravenous insulin tolerance test ( $K_{ITT}(iv)$ ) and the subcutaneous insulin 29 tolerance test ( $K_{\rm ITT}$ (sc)). We compared  $K_{\rm ITT}$ (iv) between the volunteers and patients, and examined its 30 correlation with K<sub>ITT</sub>(sc). We also examined the association of K<sub>ITT</sub>(iv) with obesity, insulin resistance-31 related parameters, and the insulin dose required for glycemic control. A total of 24 participants (seven 32 controls and 17 patients with T2DM) were studied. The mean K<sub>ITT</sub>(iv) was significantly lower in patients 33 with T2DM than in the controls (2.5%±2.1% vs. 4.5%±1.8%). In all participants, K<sub>ITT</sub>(iv) was significantly 34 correlated with the HOMA-IR values (r=-0.601, p<0.05) but not with K<sub>ITT</sub>(sc) (p=0.62). K<sub>ITT</sub>(iv) was 35 correlated positively with the serum adiponectin concentration, but negatively with the visceral fat area and 36 serum concentrations of tumor necrosis factor- $\alpha$  and branched-chain amino acids. In patients with T2DM, 37  $K_{ITT}(iv)$  and HOMA-IR values were significantly correlated with the total insulin dose required for glycemic control. Insulin resistance evaluated using intravenous insulin (K<sub>ITT</sub>(iv)) was correlated with the 38 39 HOMA-IR values, but not with the resistance evaluated using subcutaneous insulin (K<sub>ITT</sub>(sc)). The degree 40 of insulin resistance was associated with biomarkers, such as adiponectin, and with the dose of insulin 41 required for glycemic control.

42

## 44 Introduction

45	Insulin resistance is a cardinal feature of the pathogenesis of non-insulin-dependent diabetes mellitus
46	[1]. Precise estimation of insulin resistance is important to understand the mechanism underlying the
47	impairment of glycemic control and accordingly optimize the treatment for patients with diabetes.
48	The hyperinsulinemic euglycemic glucose clamp test (HEGCT) is the gold standard for evaluating
49	insulin resistance [2]. However, it is complicated and difficult to perform in many patients. The
50	homeostasis model assessment for insulin resistance (HOMA-IR value) is another test that is frequently
51	used for evaluating the insulin resistance. HOMA-IR can be performed readily and is well correlated with
52	the HEGCT [3]. However, in patients with diabetes mellitus with high fasting plasma glucose (FPG)
53	levels (who may have a decreased insulin secretion), it is less accurate as an indicator of insulin resistance
54	[4]. In addition, HOMA-IR cannot estimate insulin resistance in patients with diabetes who are receiving
55	insulin therapy [4].
56	The short insulin tolerance test (SITT) is a simple and convenient method for estimating insulin
57	resistance [5, 6]. In the SITT, regular insulin is administered intravenously, and blood samples are
58	collected sequentially for 15 min; the plasma glucose disappearance rate is then estimated [5, 6]. The K
59	index of the insulin tolerance test ( $K_{ITT}$ ) is calculated from the linear slope of the plasma glucose
60	concentration curve and correlates well with the HEGCT [3, 7]. The SITT can assess whole-body insulin
61	sensitivity even in patients with decreased insulin secretion or on insulin therapy. However, the SITT
62	carries a risk of hypoglycemia [5, 8], and $K_{\text{ITT}}$ estimation requires multiple blood sampling. Theoretically,
63	K <sub>ITT</sub> can be estimated more easily by administering insulin subcutaneously without venous blood
64	sampling, e.g., finger pricking, and using the glucose concentration in finger-prick blood. Furthermore,
65	rapid hypoglycemia is less likely to occur with subcutaneous insulin administration than with intravenous
66	insulin administration. However, the accuracy of K <sub>ITT</sub> has not been validated.
67	Previous studies have provided the $K_{ITT}$ values from intravenous SITT ( $K_{ITT}(iv)$ ) in humans [3, 5, 6,
68	7, 9]. Especially in patients with poorly controlled diabetes mellitus, $K_{ITT}(iv)$ is considered more accurate
69	than HOMA-IR because it is not affected by a decreased insulin secretory capacity. However, few studies
70	[10] have examined the association between K <sub>ITT</sub> (iv) and other parameters related to obesity and insulin
71	resistance (such as visceral fat, adiponectin, and tumor necrosis factor [TNF]-a). Such data will improve
72	the understanding of the pathogenesis of insulin resistance and help optimize the treatment in each
73	patient. Furthermore, the application of K <sub>ITT</sub> (iv) for predicting the amount of insulin required would be
74	useful in practice.
75	In the present prospective study, we calculated $K_{ITT}(iv)$ in healthy volunteers and patients with type 2
76	diabetes mellitus (T2DM). Using KITT(iv) as a reference, we then evaluated the accuracy of HOMA-IR
77	and the K <sub>ITT</sub> obtained using glucose concentration of fingertip blood (i.e., after subcutaneous insulin
-	

- 78 injection [KITT(sc)]). We also investigated the relationship between K<sub>ITT</sub>(iv) and the parameters related
  - 3

- to obesity and insulin resistance, and examined the possible role of K<sub>ITT</sub>(iv) in predicting the insulin dose
- 80 required for glycemic control in patients with T2DM.
- 81

## 82 Methods

#### 83 Study participants

- This was a single-center, randomized, crossover study with 17 patients with T2DM (who were admitted to the Hokkaido University Hospital for glycemic control) and seven healthy volunteers (controls). The registration period was from November 2016 to July 2019.
- 87 The inclusion criteria for the controls were as follows: age  $\geq$ 30 years; body mass index, >18.5 88 kg/m<sup>2</sup>; and no previous diagnosis of diabetes or impaired glucose tolerance. The inclusion criteria for the 89 patients were as follows: age  $\geq 20$  years, T2DM diagnosis based on the American Diabetes Association 90 Criteria [11], and FPG level  $\geq$  140 mg/dL during hospitalization. The exclusion criteria for the controls 91 were as follows: history of hypoglycemia (blood glucose < 60 mg/dL), untreated ischemic heart disease, 92 epilepsy, pregnancy, possible pregnancy, lactation, and researcher-determined ineligibility. The exclusion 93 criteria for the patients were as follows: unstable diabetic retinopathy, stage  $\geq 4$  diabetic nephropathy, 94 untreated ischemic heart disease, history of hypersensitivity to human regular insulin, epilepsy, 95 pregnancy, possible pregnancy, lactation, and deemed ineligible by the researcher.
- 96

### 97 Crossover assignment to the insulin tolerance test with

#### 98 intravenous or subcutaneous insulin

- After case enrollment using the central registration system by the research persons, the participants were assigned to undergo either of the following pathways: 1) the SITT first (with intravenous insulin injection), followed by an insulin tolerance test with subcutaneous insulin injection (ITTsc) or 2) the ITTsc first, followed by the SITT. This assigning of the patients was performed on a 1:1 basis by the research office, and the results were communicated to the co-investigators in writing. The two insulin tolerance tests (SITT and ITTsc) were completed within 3 days, irrespective of the order(Fig 1).
- 106

#### 107 **Pre-test preparations**

108The controls arrived at the hospital in the morning after fasting overnight to participate in the109study. Patients with T2DM, after admission to the hospital, were started on a diet (25–30 kcal/kg standard

110 body weight/day); metformin, pioglitazone, and sodium glucose transporter 2 inhibitors were withdrawn

- 111 on admission. The patients' fasting venous blood was collected the day after admission; if the FPG level
- 112 was >140 mg/dL, the patient was included in this study. The controls and patients both underwent the
- 113 SITT and ITTsc after overnight fasting.
- 114

#### 115 **SITT procedures**

- 116 The SITT was performed before breakfast. Venous blood samples were collected for
- 117 measurement of plasma glucose before and at 3, 6, 9, 12, and 15 min after an intravenous bolus injection
- 118 of regular human insulin (0.1 U/kg bodyweight; Eli Lilly®, Eli Lilly®, Eli Lilly and Company, IN, USA). Fifteen
- 119 minutes after the insulin injection, the test was completed by injecting 20 mL of 50% glucose solution.
- 120 K<sub>ITT</sub> [now labelled K<sub>ITT</sub>(iv)] was calculated from the linear slope of the curve of plasma glucose
- 121 concentrations at the 3–15-min timepoints using the Lundback equation [12].
- 122

#### 123 **ITTsc procedures**

124The ITTsc was performed before breakfast. Finger-prick blood samples were collected for the125measurement of blood glucose before, and at 3, 6, 9, 12, 15, 30, 45, 60, 75, 90, and 120 min after a126subcutaneous injection of regular human insulin (0.1 U/kg bodyweight). The K<sub>ITT</sub> (now labelled K<sub>ITT</sub>(sc))127was calculated from the linear slope of the curve of finger-pick blood glucose concentrations at the 30-128120 min timepoints using the Lundback equation.

129

#### 130 Clinical parameters related to insulin resistance

131 The waist circumference and waist-to-hip ratio before breakfast were measured during the first 132 ITT. The visceral fat area (VFA) was calculated using the bioimpedance method (BIM; InBody770<sup>®</sup>, 133 InBody Japan Inc., Tokyo, Japan). We measured the fasting serum C-peptide immunoreactivity (CPR); 134 levels of fasting immunoreactive insulin (F-IRI), adiponectin, leptin, and TNF- $\alpha$ ; and concentrations of 135 plasma amino acids (AA) and branched chain AAs (BCAA) using the baseline (0 min) blood sample from 136 the SITT or ITTsc (whichever was performed first). The HOMA-IR values were calculated using the 137 following formula: HOMA-IR = (FPG  $[mg/dL] \times F$ -IRI  $[\mu U/mL]$ )/405. F-IRI and the HOMA-IR values 138 were not determined in insulin-treated patients. 139

#### 140 Insulin treatment after SITT/ITTsc

After the SITT and ITTsc, all 17 patients with T2DM were treated with multiple daily insulin

142 injections. Basal and bolus insulin doses were adjusted until the FPG levels were  $\leq 130 \text{ mg/dL}$  and the

143 postprandial plasma glucose levels were  $\leq 180 \text{ mg/dL}$ . The total insulin dose used for glycemic control

- 144 was then calculated. Using K<sub>ITT</sub>(iv) and the HOMA-IR value, equations by which the total insulin dose
- 145 (/body weight) could be calculated were formed.
- 146

#### 147 Statistical analyses

- 148Data are expressed as mean  $\pm$  standard deviation. The required sample size was determined to149be 19 after assuming a correlation coefficient of 0.6 between K<sub>ITT</sub>(iv) and K<sub>ITT</sub>(sc), a power of 80%, and a150significance level of 5%. However, the actual sample size was set at 24, assuming a 20% dropout rate.
- 151 We compared  $K_{ITT}(iv)$  between the controls and patients with T2DM. We then examined the 152 correlation of K<sub>ITT</sub>(iv) with the HOMA-IR value and K<sub>ITT</sub>(sc) using Pearson's correlation coefficient 153 analysis. The intraclass correlation coefficient (ICC) was also used to assess the relationship between 154 K<sub>ITT</sub>(iv) and K<sub>ITT</sub>(sc). We further analyzed the association of K<sub>ITT</sub>(iv) with VFA and other parameters 155 related to obesity and insulin resistance using a Pearson's correlation coefficient analysis. In addition, the 156 association of K<sub>1TT</sub>(iv) and the HOMA-IR value with the daily insulin dose required for glycemic control 157 was evaluated in patients with diabetes, using Pearson's correlation coefficient analysis. The frequency of 158 adverse events was analyzed using the McNemar test. All analyses were performed using JMP (SAS 159 institute, Cary, NC, USA).

Written informed consent was obtained from all individuals prior to participation in the study.
This study was approved by the ethics committee of the Hokkaido University Hospital (date of approval
25 October 2016; approval no. 016-0014) and registered in the University Hospital Medical Information
Network (UMIN000024453).

164

### 165 **Results**

166 The clinical characteristics of the participants are summarized in Table 1. Among the 17 167 patients with T2DM, eight (47.1%) were treated with antihypertensive agents, eight (47.1%) with 168 hyperlipidemic agents, two (11.8%) with sulfonylurea, five (29.4%) with insulin, six (35.3%) with 169 metformin, five (29.4%) with dipeptidyl peptidase 4 inhibitors, and two (11.8%) with sodium glucose 170 cotransporter 2 inhibitors.

171

#### 172 Table 1. Characteristics of the study participants

	Healthy controls	Patients with type p values
	fieating controls	2 diabetes mellitus
n (men/women)	7 (4/3)	17 (14/3)

se
5

Age (years)	39 3±13 3	$62.2\pm23.0$	<0.05
	(2.7) 10.2	(9.5+10.1	0.10
Body weight (kg)	62./±18.3	68.5±19.1	0.19
Body mass index (kg/m <sup>2</sup> )	22.3±4.8	24.9±5.2	< 0.05
Waist circumference (cm)	78.4±12.7	93.6±16.4	< 0.05
Waist-to-hip ratio	0.8±0.1	1.0±0.1	< 0.05
Visceral fat area (cm <sup>2</sup> )	55.5±33.9	92.8±63.0	< 0.05
Fasting plasma glucose (mg/dL)	94.0±15.2	172.1±93.6	< 0.05
Immunoreactive insulin (µIU/mL)	4.7±3.7	4.5±4.3	0.67
Fasting C-peptide radioactivity (ng/mL)	1.2±0.6	1.7±1.0	< 0.05
HOMA-IR	1.1±0.9 <sup>a</sup>	1.9±2.3 <sup>b</sup>	0.09
K <sub>ITT</sub> (iv) (%)	4.5±1.8	2.5±2.1	< 0.05
K <sub>ITT</sub> (sc) (%)	0.3±0.3	0.5±0.5	< 0.05
Adiponectin (µg/mL)	10.9±10.1	5.9±4.0	< 0.05
Leptin (ng/mL)	8.1±6.7	10.0±8.6	0.31
Adiponectin/Leptin	1.5±1.2	0.7±1.1	< 0.05
Tumor necrosis factor-a (pg/mL)	0.6±0.9	1.2±0.5	< 0.05
Branched chain amino acid/total amino acid	0.15±0.04	0.16±0.03	< 0.05

<sup>a</sup> n=6

<sup>b</sup> n=11

HOMA-IR, homeostatic model assessment for insulin resistance;  $K_{ITT}(iv)$ , K index of the intravenous insulin tolerance test;  $K_{ITT}(sc)$  calculated from the linear slope of the curve of plasma glucose concentrations at the 30–120-min timepoints using the Lundbaek equation

174	The mean $K_{ITT}(iv)$ was significantly higher in the controls than in the patients (4.5%±1.8% vs.
175	2.%5±2.1%). Conversely, the mean HOMA-IR value was lower in the controls than in the patients
176	(1.1±0.9 vs. 1.9±2.3). However, the mean $K_{ITT}(sc)$ did not differ significantly between the controls and
177	the patients (0.3%±0.3% vs. 0.5%±0.5%).
178	In all participants, there was a significant correlation between $K_{ITT}(iv)$ and the HOMA-IR value
179	(r=-0.601, p<0.05; Fig 2a); conversely, there was no significant correlation between $K_{ITT}(iv)$ and $K_{ITT}(sc)$
180	(ICC=0, p=0.62; Fig 2b). As shown in Fig 3, K <sub>ITT</sub> (iv) was negatively correlated with FPG (r=-0.673,
181	p<0.05), CPR (r=-0.489, p<0.05), TNF-α (r=-0.648, p<0.05), BCAA/total AA (r=-0.64, p<0.05), and
182	VFA (BIM; r=-0.444, p<0.05); it was positively correlated with the adiponectin concentration (r=0.487,
183	p<0.05).
184	

- 185 Fig 2. Relationship of  $K_{ITT}(iv)$  with the HOMA-IR value and  $K_{ITT}(sc)$ .
  - 7

186 (a) $K_{ITT}$ (iv) was significantly correlated with the HOMA-IR value (r=-0.601, p<0.05). (b)  $K_{ITT}$ (iv) was not 187 correlated with K<sub>ITT</sub>(sc). 188 KITT(iv), K index of the intravenous insulin tolerance test; HOMA-IR, homeostasis model assessment 189 for insulin resistance; K<sub>ITT</sub>(sc), K index of the subcutaneous insulin tolerance test 190 191 Fig 3. Relationship of K<sub>ITT</sub>(iv) with other parameters. 192 (a) $K_{ITT}(iv)$  was negatively correlated with the visceral fat area (r=-0.444, p<0.05), (b) fasting plasma 193 glucose (r=-0.673, p< 0.05), (c)fasting serum C-peptide (r=-0.489, p< 0.05), (e)TNF- $\alpha$  (r=-0.648, 194 p < 0.05), and (f)BCAA/total AA (r=-0.64, p < 0.05). (d)It was positively correlated with the adiponectin 195 level (r=0.487, p<0.05). 196  $K_{ITT}(iv)$ , K index of the intravenous insulin tolerance test; TNF- $\alpha$ , tumor necrosis factor- $\alpha$ ; BCAA, 197 branched-chain amino acid; AA, amino acid 198 199 In the 17 patients with T2DM, the mean total insulin dose used for glycemic control was 200  $36.2\pm28.1$  U/day, and the mean total insulin dose/body weight was  $0.5\pm0.4$  U/kg. The mean total insulin 201 dose/body weight was negatively correlated with  $K_{TTT}(iy)$  (r=-0.550, p<0.05), and it was calculated using 202 the following regression equation (Fig 4a): total insulin dose/kg =  $0.78-0.10 \times K_{ITT}$  (iv). The mean total 203 insulin dose/body weight was positively correlated with the HOMA-IR value (r=0.806, p<0.05), and it 204 was calculated using the following regression equation (Fig 4b): total insulin dose/kg =  $0.23+0.15\times$ 205 HOMA-IR value. 206 207 Fig 4. Relationship of K<sub>ITT</sub>(iv) and the HOMA-IR value with the mean total insulin dose/kg. 208 (a) $K_{ITT}(iv)$  was significantly correlated with the mean total insulin dose per body weight (r=-0.550, 209 p < 0.05); this was estimated using with the following regression equation: total insulin dose/kg = 0.78-210 $0.10 \times K_{ITT}(iv)$ . (b)The HOMA-IR value was also significantly correlated with the mean total insulin dose 211 per body weight (r=0.806, p<0.05); this was estimated using with the following regression equation: total 212 insulin dose/kg =  $0.23+0.15 \times HOMA-IR$ . 213  $K_{\rm ITT}$ (iv), K index of the intravenous insulin tolerance test; HOMA-IR, homeostasis model assessment for 214 insulin resistance 215 216 Seven and two adverse events occurred in participants undergoing the SITT and ITTsc, 217 respectively. All adverse events were hypoglycemia. No significant difference was observed in the 218 frequency of adverse events between participants undergoing the SITT and the ITTsc. 219

## 220 **Discussion**

221 In the present study, we prospectively studied seven healthy controls and 14 patients with 222 T2DM and evaluated their insulin resistance using  $K_{ITT}(iv)$ . The following four main results were 223 obtained: 1) the K<sub>ITT</sub>(iv) of patients with T2DM was 2.5%±2.1%, which was significantly lower than that 224 of the controls  $(4.5\%\pm1.8\%)$ ; 2) K<sub>ITT</sub>(iv) was significantly correlated with the HOMA-IR value but not 225 with K<sub>ITT</sub>(sc); 3) K<sub>ITT</sub>(iv) was significantly correlated with VFA and the serum glucose, CPR, TNF-a, 226 BCAA/total AA, and adiponectin concentrations; and 4) the total insulin dose required for glycemic 227 control was correlated with K<sub>ITT</sub>(iv) and the HOMA-IR value, and it was estimated using an equation in 228 patients with T2DM.

229 HOMA-IR values are widely used as indices of insulin resistance [13, 14]; however, their 230 reliability decreases when the insulin secretion is reduced and hyperglycemia occurs [4]. In the present 231 study, there was a significant correlation between the HOMA-IR value and  $K_{TTT}(iv)$ , suggesting its 232 applicability as an index of insulin resistance even in a cohort including healthy volunteers and patients 233 with poorly controlled T2DM. The significant correlation between the HOMA-IR value and  $K_{\rm HTT}(iv)$  may 234be attributed to the fact that the FPG level was not very high and the decrease in insulin secretion was 235 only mild in our patients with T2DM. A previous study revealed that the HOMA-IR value is a useful 236 index for determining insulin resistance at an FPG range of 80-170 mg/dL in obese Japanese patients 237 with T2DM [4]. In fact, in this study, the mean FPG level of patients with T2DM was approximately 170 238 mg/L (Table 1), and the correlation observed between CPR and  $K_{\rm ITT}$  supports the fact that the HOMA-IR 239 value can be used as an effective index in this group (Fig 2b). In addition, the association between the two 240 indices was observed even in the controls, which might have led to the significant correlation between the 241 two indices in all study participants. Although the HOMA-IR data in this study were exclusive of patients 242 on insulin therapies for diabetes, Okita et al. [10] reported that KITT in such patients can be a useful 243 indicator of insulin resistance using the euglycemic clamp test.

244 We expected that K<sub>ITT</sub>(sc) would be correlated with K<sub>ITT</sub>(iv) because the pattern of glucose 245level changes, unlike the rate of action, in an individual may be similar between intravenous and 246 subcutaneous routes of insulin administration. In addition, the accuracy of finger-prick tests for blood 247 glucose measurement has substantially improved [15]. However, contrary to our expectations, there was 248no significant correlation between  $K_{ITT}(iv)$  and  $K_{ITT}(sc)$  (ICC=0). A possible explanation for this 249 dissociation may be the instability of the insulin absorption rate due to differences in the skinfold 250 thickness and subcutaneous blood flow [16, 17]. Exercise, smoking, and body position are also reported 251 to affect insulin absorption [16, 17]. However, in this study, all patients were resting, had stopped 252 smoking, and were sitting; thus, we considered these factors to have no effect. Previous studies [18-21] 253 have compared glycemic control between intravenous and subcutaneous routes of insulin administration 254 mainly in intensive care units; however, to our knowledge, there are no crossover studies comparing the 255 two routes in the same individuals.

256

In this study, K<sub>ITT</sub>(iv) was correlated with various clinical parameters associated with obesity

257 and insulin resistance, including VFA, adiponectin, tumor necrosis factor alpha (TNF- $\alpha$ ), and branched 258 chain amino acids (BCAA)/total AA. Obesity and visceral fat are closely associated with insulin 259 resistance; thus, the significant correlation between KITT(iv) and the VFA was considered reasonable 260 [10, 22]. Low adiponectin levels were also associated with an increased risk of insulin resistance [23], and 261 TNF- $\alpha$  is a strong inhibitor of adiponectin promoter activity [24]. In non-obese, non-diabetic individuals, 262no significant correlation was observed between adipose tissue TNF- $\alpha$  mRNA content and K<sub>ITT</sub>(iv) [25]. 263 However, when including patients with T2DM and a tendency for obesity, positive and negative 264correlations of  $K_{ITT}(iv)$  with adiponectin and TNF- $\alpha$ , respectively, were observed in prior investigations 265 similar to in our study [10]. In addition, in our study, K<sub>ITT</sub>(iv) was negatively associated with BCAAs/total 266 AAs. This corroborates the findings of prior studies that revealed a significant association between insulin 267resistance and BCAAs [26, 27]. In fact, BCAAs were reported to accumulate under conditions of insulin resistance [28]; furthermore, a positive association of insulin resistance with valine, one of the three 268 269 BCAAs, has been reported in Japanese healthy individuals [29].

270 To the best of our knowledge, this is the first report on a regression equation for calculating the 271 insulin dose required for glycemic control based on  $K_{ITT}(iv)$ . It is useful for adjusting the insulin dose and 272 avoiding hypoglycemic events. Notably, the correlation coefficient was better for the HOMA-IR value 273 (r=0.806) than for  $K_{ITT}$ (iv) (r=-0.550), suggesting that the HOMA-IR value is an easily applicable 274parameter that helps estimate the insulin dose required for glycemic control.

275This study had several limitations. First, the sample size was small and the study was 276 conducted at a single center. Second, there was significant heterogeneity among participants in terms of 277 the age, sex, comorbidities, and treatment regimens (in patients with T2DM). The first and second 278 limitations precluded robust statistical analyses. Finally, we did not verify the reproducibility and 279 reliability of the equations for calculating the total insulin dose using the HOMA-IR value and  $K_{ITT}(iv)$ .

280 In conclusion,  $K_{TTT}(iv)$  was associated with the HOMA-IR value and insulin resistance-related 281 parameters (such as VFA, adiponectin, and BCAAs). K<sub>ITT</sub>(iv) is an index of insulin resistance that can be 282 applied in clinical practice; along with HOMA-IR, it may be useful for efficiently adjusting insulin doses. 283

#### Acknowledgements 284

285 None

286

#### **Data availability** 287

288 The date presented in this manuscript are accessible and can be provided on reasonable request to the 289 corresponding author. 290

## 292 **References**

293	1.	DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion
294		responsible for NIDDM. Diabetes. 1988;37: 667-687.
295	2.	Godsland IF, Stevenson JC. Insulin resistance: syndrome or tendency? Lancet. 1995;346:
296		100-103.
297	3.	Bonora E, Moghetti P, Zancanaro C, Cigolini M, Querena M, Cacciatori V, et al. Estimates
298		of in vivo insulin action in man: comparison of insulin tolerance tests with euglycemic and
299		hyperglycemic glucose clamp studies. J Clin Endocrinol Metab. 1989;68: 374-378.
300	4.	Ono T, Shiga N, Taneda Y, Umemura S. The fasting-plasma glucose range in which insulin
301		resistance measured by homeostasis model assessment correlates with euglycemic clamping.
302		J Japan Diab Soc. 1999;42: 1005-1011.
303	5.	Young RP, Critchley JA, Anderson PJ, Lau MS, Lee KK, Chan JC. The short insulin
304		tolerance test: feasibility study using venous sampling. Diabet Med. 1996;13: 429-433.
305	6.	Hirst S, Phillips DI, Vines SK, Clark PM, Hales CN. Reproducibility of the short insulin
306		tolerance test. Diabet Med. 1993;10: 839-1842.
307	7.	Akinmokun A, Selby PL, Ramaiya K, Alberti KG. The short insulin tolerance test for
308		determination of insulin sensitivity: a comparison with the euglycaemic clamp. Diabet Med.
309		1992;9: 432-427.
310	8.	Chen CC, Wang TY, Hsu SY, Chen RH, Chang CT, Chen SJ. Is the short insulin tolerance
311		test safe and reproducible? Diabet Med. 1998;15: 924-927.
312	9.	Graci S, Baratta R, Degano C, Luppa A, Vigneri R, Frittitta L, et al. The intravenous insulin
313		tolerance test is an accurate method for screening a general population for insulin resistance
314		and related abnormalities. J Endocrinol Invest. 1999;22: 472-475.
315	10.	Okita K, Iwahashi H, Kozawa J, Okauchi Y, Funahashi T, Imagawa A, et al. Usefulness of
316		the insulin tolerance test in patients with type 2 diabetes receiving insulin therapy. J
317		Diabetes Investig. 2014;5: 305-312.
318	11.	American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes
319		Care. 2010;33: S62-S69.
320	12.	Lundbaek K. Intravenous glucose tolerance as a tool in definition and diagnosis of diabetes
321		mellitus. Br Med J. 1962;1: 1507-1513.
322	13.	González-González JG, Violante-Cumpa JR, Zambrano-Lucio M, Burciaga-Jimenez E,
323		Castillo-Morales PL, Garcia-Campa M, et al. HOMA-IR as a predictor of health outcomes
324		in patients with metabolic risk factors: a systematic review and meta-analysis. High Blood
325		Press Cardiovasc Prev. 2022;29: 547-564.
326	14.	Tahapary DL, Pratisthita LB, Fitri NA, Marcella C, Wafa S, Kurniawan F, et al. Challenges

327		in the diagnosis of insulin resistance: focusing on the role of HOMA-IR and
328		Tryglyceride/glucose index. Diabetes Metab Syndr. 2022;16: 102581.
329	15.	King F, Ahn D, Hsiao V, Porco T, Klonoff DC. A review of blood glucose monitor
330		accuracy. Diabetes Technol Ther. 2018;20: 843-856.
331	16.	Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients.
332		Influence of species, physico-chemical properties of insulin and physiological factors. Dan
333		Med Bull. 1991;38: 337-346.
334	17.	Gradel AKJ, Porsgaard T, Lykkesfeldt J, Seested T, Gram-Nielsen S, Kristensen NR, et al.
335		Factors affecting the absorption of subcutaneously administered insulin: effect on
336		variability. J Diabetes Res. 2018;2018: 1205121.
337	18.	Neff K, Donegan D, MacMahon J, O'Hanlon C, Keane N, Agha A, et al. Management of
338		parenteral nutrition associated hyperglycaemia: a comparison of subcutaneous and
339		intravenous insulin regimen. Ir Med J. 2014;107: 141-143.
340	19.	Bodur HA, Saygili F, Saygili S, Doganay LH, Yesil S. Continuous infusion of subcutaneous
341		compared to intravenous insulin for tight glycaemic control in medical intensive care unit
342		patients. Anaesth Intensive Care. 2008;36: 520-527.
343	20.	Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion
344		reduces the incidence of deep sternal wound infection in diabetic patients after cardiac
345		surgical procedures. Ann Thorac Surg. 1999;67: 352-360.
346	21.	Pezzarossa A, Taddei F, Cimicchi MC, Rossini E, Contini S, Bonora E, et al. Perioperative
347		management of diabetic subjects. Subcutaneous versus intravenous insulin administration
348		during glucose-potassium infusion. Diabetes Care. 1988;11: 52-58.
349	22.	Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and
350		type 2 diabetes. Nature. 2006;444: 840-846.
351	23.	Moon HU, Ha KH, Han SJ, Kim HJ, Kim DJ. The association of adiponectin and visceral
352		fat with insulin resistance and $\beta$ -cell dysfunction. J Korean Med Sci. 2018;34: e7.
353	24.	Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al.
354		PPARgamma ligands increase expression and plasma concentrations of adiponectin, an
355		adipose-derived protein. Diabetes. 2001;50: 2094-2099.
356	25.	Frittitta L, Youngren JF, Sbraccia P, D'Adamo M, Buongiorno A, Vigneri R, et al. Increased
357		adipose tissue PC-1 protein content, but not tumour necrosis factor-alpha gene expression, is
358		associated with a reduction of both whole body insulin sensitivity and insulin receptor
359		tyrosine-kinase activity. Diabetologia. 1997;40: 282-289.
360	26.	Allam-Ndoul B, Guénard F, Garneau V, Barbier O, Pérusse L, Vohl M. Associations
361		between branched chain amino acid levels, obesity and cardiometabolic complications.
362		Integr Obesity Diabetes. 2015;1: 157-162.

363	27.	Elshorbagy A, Jernerén F, Basta M, Basta C, Turner C, Khaled M, et al. Amino acid
364		changes during transition to a vegan diet supplemented with fish in healthy humans. Eur J
365		Nutr. 2017;56: 1953-1962.
366	28.	Lynch CJ, Adams SH. Branched-chain amino acids in metabolic signalling and insulin
367		resistance. Nat Rev Endocrinol. 2014;10: 723-736.
368	29.	Takashina C, Tsujino I, Watanabe T, Sakaue S, Ikeda D, Yamada A, et al. Associations
369		among the plasma amino acid profile, obesity, and glucose metabolism in Japanese adults
370		with normal glucose tolerance. Nutr Metab (Lond). 2016;13: 5



# **CONSORT 2010 Flow Diagram**



Analysed (n= 12)

Excluded from analysis (give reasons) (n=0

Analysed (n=12) • Excluded from analysis (give reasons) (n=0)

# Figure

)



# Figure



Figure

# a. KITT(iv) vs mean total insulin dose/kg



# b. HOMA-IR vs mean total insulin dose/kg



Figure